Research programme: oligonucleotide-based therapeutics - SynthenaAlternative Names: SYN 416; SYN 510
Latest Information Update: 28 Feb 2017
At a glance
- Originator Synthena
- Class Antisense oligonucleotides; Oligonucleotides
- Mechanism of Action Antisense RNA modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 28 Feb 2017 Preclinical trials in Duchenne muscular dystrophy in Switzerland (Synthena pipeline, February 2017)